So the bad news is Intrepid trials are running 6 months behind.
They are bringing on new sites.
The Good news is
"On a positive note, the incidence of serious adverse events or SAEs continues to be very
low as does mortality. We recently completed the reproductive toxicology studies that are necessary
to initiate a pivotal trial and found no effects whatsoever on male or female fertility or reproductive
fitness."
So does the Serious adverse events and low mortality, have a statistically significant result which makes NNZ-2566 approveable.
I imagine somebody at the AGM has got a definitive answer to that question.
I like a punt, so I would back it in that this will eventually be an approved drug.
At these prices the odds are too heavily stacked my way not to have a decent punt.
- Forums
- ASX - By Stock
- Ann: CEO's address to AGM
So the bad news is Intrepid trials are running 6 months behind....
-
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.81 |
Change
-0.335(2.55%) |
Mkt cap ! $1.651B |
Open | High | Low | Value | Volume |
$13.03 | $13.06 | $12.75 | $3.695M | 286.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 2824 | $12.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.81 | 844 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 72 | 12.800 |
11 | 1275 | 12.790 |
6 | 1441 | 12.780 |
7 | 2342 | 12.770 |
7 | 3799 | 12.760 |
Price($) | Vol. | No. |
---|---|---|
12.810 | 416 | 8 |
12.820 | 868 | 7 |
12.830 | 1244 | 11 |
12.840 | 1303 | 7 |
12.850 | 974 | 4 |
Last trade - 13.05pm 11/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online